Wargny, 2,794 patient metformin prophylaxis study: 28% lower mortality [p=0.03] and 15% higher hospital discharge [p=0.02] https://c19p.org/wargny
copied to clipboard
Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study
et al., Diabetologia, doi:10.1007/s00125-020-05351-w
Retrospective 2,796 hospitalized diabetes patients with COVID-19 in France, showing lower mortality with metformin use. CORONADO. NCT04324736.
|
risk of death, 28.3% lower, RR 0.72, p = 0.03, treatment 247 of 1,553 (15.9%), control 330 of 1,241 (26.6%), NNT 9.4, adjusted per study, odds ratio converted to relative risk, multivariable, day 28.
|
|
risk of no hospital discharge, 14.8% lower, RR 0.85, p = 0.02, treatment 690 of 1,553 (44.4%), control 702 of 1,241 (56.6%), NNT 8.2, adjusted per study, odds ratio converted to relative risk, multivariable, day 28.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Wargny et al., 2/17/2021, retrospective, France, Europe, peer-reviewed, 43 authors, study period 10 March, 2020 - 10 April, 2020, trial NCT04324736.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.